Research Library / GH Axis / CJC-1295
GH Axis researchCJC-1295
CJC-1295 DAC · GHRH analog
A modified GHRH analog designed to extend exposure through covalent binding to circulating albumin. The listed community example (dac weekly schedule) describes 1–2 mg per administration, once weekly, via subcutaneous; this is not a validated dosing recommendation. An illustrative 5 mg vial at an assumed 2 mL final volume yields 2.5 mg/mL; diluent compatibility remains product-specific. For research and education only, not personal medical guidance.
Quick Reference
- Example vial
- 5mg
- Assumed final volume
- 2mL · not an amount to add
- Concentration
- 2.5mg/mL · conditional arithmetic
- One U-100 marking
- 25mcg in 0.01 mL
Hypothetical vial math does not reproduce a study formulation or verify a diluent, sterility or storage period.
Research schedules
Single 30–60 μg/kg or repeated 20–30 μg/kg · subcutaneous; studies lasted 28 and 49 days; repeated administrations weekly or biweekly
Healthy adults ages 21–61JCEM, 2006No established clinical dose, route or frequency
Human evidence is absent, limited or not confirmatoryFDA safety-risk resourceReported schedule context
- Range
- 1–2 mg/week
- Frequency
- One or two administrations weekly
- Route
- Subcutaneous
- Reported half-life
- 5.8–8.1 days in human SC DAC studies
- Reported cycle
- 8–12 weeks commonly reported
This result applies to DAC-containing CJC-1295, not modified GRF/no-DAC. The community cycle is not the 28- or 49-day trial duration.
Cross-reference reviewed October 2026. Half-life and cycles retain this source context.| Context / phase | Amount | Schedule total | Frequency | Timing | Route | Evidence |
|---|---|---|---|---|---|---|
| DAC weekly schedule | 1–2 mg | 1–2 mg/week | Once weekly | Same day each week | Subcutaneous | Community-reported |
| DAC divided schedule | 0.5–1 mg | 1–2 mg/week | Twice weekly | Evenly spaced | Subcutaneous | Community-reported |
Repeated community reports do not establish identity, safety, effectiveness or an appropriate exposure. Component schedules do not validate a same-vial blend.
Vial calculator
Linked to Quick Reference and compatible supply calculations.
Read the needle-side edge of the black stopper. Liquid tint is illustrative.
Scale illustration · one U-100 marking = 0.01 mL.
Arithmetic yield at this example amount
5 example portions per vial
5 full amounts; 0 mg remaining. Yield is not a storage or reuse period.
See the calculation
Concentration = vial content ÷ final volume. Volume = example amount ÷ concentration. U-100 markings = mL × 100.
Original example & formulation context
1 mg · 2.5 mg/mL · 0.4 mL · 40 units
FDA assessments identify inconsistent CJC naming, salt-form differences and formulation sensitivity. DAC-containing CJC-1295 and modified GRF/no-DAC material must be identified separately. The calculation assumes the stated final solution volume, which may differ from liquid added. It does not verify dissolution, solvent compatibility, sterility, chemical stability or storage. See the source-linked preparation notes below.
Supplies & vial yield
5 mg (hypothetical) · 2 mL assumed final solution volume; diluent product-specific · DAC weekly schedule
Vial counts and final solution totals below use the selected 5 mg example at 2 mL. The original schedule totals stay unchanged.
Schedule phases used for planning
| Phase | Amount | Frequency | Weekly total |
|---|---|---|---|
| Selected planning schedule | 1–2 mg | Once weekly | 1–2 mg/week |
Peptide vials
| Horizon | Total | Vials* |
|---|---|---|
| 4 weeks | 4–8 mg | 1–2 × 5 mg |
| 8 weeks | 8–16 mg | 2–4 × 5 mg |
| 12 weeks | 12–24 mg | 3–5 × 5 mg |
Liquid planning
| Horizon | Final volume* | Diluent supplies |
|---|---|---|
| 4 weeks | 2–4 mL | Not established |
| 8 weeks | 4–8 mL | Not established |
| 12 weeks | 6–10 mL | Not established |
Administration count
| Horizon | Administrations |
|---|---|
| 4 weeks | 4 |
| 8 weeks | 8 |
| 12 weeks | 12 |
Original schedule counts. Check the calculated volume against syringe capacity; no split-dose technique is assigned.
Original vial-life context
4 weeks: 2.5–5 administrations
8 weeks: 2.5–5 administrations
12 weeks: 2.5–5 administrations
Applies to the original planning basis above; not a product stability period.
Ranges reflect the low and high ends of the selected displayed schedule (community-reported). Vials are rounded up; one new U-100 syringe is counted per subcutaneous administration. Liquid totals are conditional final solution volumes, not verified quantities to add. Diluent bottle counts are withheld pending product-specific preparation instructions. Arithmetic does not establish storage or reuse periods.
*Conditional mass and final-volume arithmetic. No stability, sterility, safe reuse period or verified diluent quantity is established. Cleansing materials, sterile supplies, labels and sharps disposal follow the actual research procedure.
Protocol overview & research context
- Identity
- CJC-1295 · CJC-1295 DAC · GHRH analog
- Evidence / status
- Phase I. Investigational — not FDA approved
- Clinical route, frequency & duration
Healthy-adult studies: Single 30–60 μg/kg or repeated 20–30 μg/kg · subcutaneous; studies lasted 28 and 49 days; repeated administrations weekly or biweekly
Evidence landscape: No established clinical dose, route or frequency
- Community purpose
- Longer-duration GH and IGF-1 support, recovery, sleep, and body-composition discussions.
- Reported timing / route
- One or two administrations weekly · Subcutaneous. Schedule-specific timing remains in the Community tab.
- Reported half-life
- 5.8–8.1 days in human SC DAC studies · community-reference context, not a shelf life.
- Reported cycle
- 8–12 weeks commonly reported. Planning horizons do not establish a validated cycle.
Loading, titration and maintenance
A separate loading phase is not identified in this library entry. Titration, maintenance and stopping rules depend on the specific product or study; a listed range is not automatically an escalation plan.
Reconstitution & formulation
FDA assessments identify inconsistent CJC naming, salt-form differences and formulation sensitivity. DAC-containing CJC-1295 and modified GRF/no-DAC material must be identified separately.
Other vehicles and approaches discussed
Vendor accounts describe water and acidified preparations and report clouding or gel-like material. This does not establish an acid requirement for every salt, sequence or DAC form.
- Evidence context
- Product / laboratory / report distinctions apply
- Cloudiness / gel signal
- Identity / salt ambiguity and reported dissolution problems
- Product details to verify
- Verify the exact product, sequence/salt form, buffer and excipients, concentration, route, container and product-specific storage instructions.
Sources apply to the named product, laboratory method or report only. Laboratory solvents and community repetition do not establish an injectable preparation, sterility, chemical stability or a beyond-use period. No solvent-mixing or salvage recipe is provided.
Preparation references reviewed October 20, 2026.
Preparation documentation checklist
- Confirm identity, nominal content, salt form, buffer and excipients.
- Verify the actual product's diluent, amount to add and intended method.
- Calculate concentration from final solution volume, and cross-check units.
- Record lot, concentration, diluent, preparation date, storage and discard instructions.
This checklist does not replace a validated preparation procedure.
Storage, clarity & stability
- Unopened product
- Follow its documented temperature, light protection, shipping and expiration requirements.
- Prepared material
- Chemical stability and microbial safety are formulation-specific. A diluent bottle's discard period does not establish the compound's storage period.
- Visible-change context
- Identity / salt ambiguity and reported dissolution problems
Unexpected cloudiness, particles or gel
For a product intended to form a clear solution, do not use or attempt to salvage unexpected persistent clouding, strings, precipitate, thickening or gel. Labeled suspensions, including some triptorelin depots, have their own expected appearance and instructions.
Why vial yield does not establish shelf life
Arithmetic portions assume the material remains usable. Chemical degradation, contamination, handling losses and required discard limits may reduce practical yield. Freezing, warming, acidifying or further diluting cannot be assumed to restore quality.
No universal refrigerated, room-temperature or 90-day beyond-use period is assigned by the calculator.
How it works
Long-acting growth hormone–releasing hormone analog
A modified GHRH analog designed to extend exposure through covalent binding to circulating albumin.
Community-reported purpose
Longer-duration GH and IGF-1 support, recovery, sleep, and body-composition discussions.
Reported purposes and marketing use-cases are not an approved indication or proof of efficacy.
Clinical findings & study landscape
Healthy-adult studies
Protocol: Single 30–60 μg/kg or repeated 20–30 μg/kg · subcutaneous; studies lasted 28 and 49 days; repeated administrations weekly or biweekly
Population: Healthy adults ages 21–61
Read the cited evidenceEvidence landscape
Protocol: No established clinical dose, route or frequency
Population: Human evidence is absent, limited or not confirmatory
Read the cited evidenceFindings apply to the tested product, population and methods. A registry listing, mechanistic study or evidence-landscape link is not itself proof of efficacy or validation of an online vial.
Safety, evidence limits & regulatory status
Compound-specific safety context
Early studies reported injection-site reactions, flushing, headache and transient gastrointestinal symptoms. Separately, FDA identifies serious increased-heart-rate and systemic vasodilatory reactions. Long-term safety is not established; DAC data do not validate no-DAC products.
Development and regulatory status
Investigational — not FDA approved
Approval of a named product does not extend to every vial, formulation, route, blend or indication carrying a related name.
What this guide cannot establish
The library does not authenticate a product or determine a personal starting dose, missed-dose rule, restart regimen, interaction plan or combination protocol. Study schedules, community reports and vial calculations retain separate evidence labels.
Frequently asked questions
What is CJC-1295?
A modified GHRH analog designed to extend exposure through covalent binding to circulating albumin.
Long-acting growth hormone–releasing hormone analog
Does vial strength mean the amount per administration?
No. A vial's label states nominal contents. The amount used in a study belongs to its assigned product and protocol. Changing vial strength changes concentration and yield, not the study's assigned amount.
Why does changing final volume change the U-100 value?
A larger final volume reduces concentration for the same mass. U-100 markings are volume measurements: one marking equals 0.01 mL. They are not biological international units of a peptide.
What happens when a calculation exceeds one syringe or vial?
Available mass and syringe capacity are separate limits. The calculator flags a result above 1 mL; it does not provide a splitting or combining technique.
Is there a loading phase or standard cycle?
A separate loading phase is not identified in this entry. Do not infer one from a range of reported amounts.
8–12 weeks commonly reported
Which diluent and storage period should this material use?
FDA assessments identify inconsistent CJC naming, salt-form differences and formulation sensitivity. DAC-containing CJC-1295 and modified GRF/no-DAC material must be identified separately.
Calculation examples do not establish solvent compatibility, sterility or shelf life.
Where do I track or calculate a multi-phase schedule?
The Free Planner supports saved research examples and multi-phase planning. This guide's calculator is local to the page and does not save a protocol automatically.
Open Free PlannerReferences & evidence trail
- Clinical / regulatory / evidence landscapeJCEM, 2006: Healthy-adult studies
- Clinical / regulatory / evidence landscapeFDA safety-risk resource: Evidence landscape
- Regulator assessmentFDA CJC-1295 assessment (2024)
- Community/vendor report — unvalidatedVendor dissolution/gelling report
Clinical sources remain attached to their studies; laboratory and community formulation sources retain their own limits. Preparation review dates do not imply that every clinical study was newly reviewed today.
Independent educational research reference. Not medical advice or an individualized dosing recommendation.